What one share of Moleculin Biotech holds
We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Moleculin Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$9.65 |
| Cash and investments | $1.02 |
| Book value | $1.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.00 | −$1,032 | $36.22 | −$1,096 | — | $1,126 |
| 2019 | $0.00 | −$729.62 | $2.87 | −$953.12 | — | $766.15 |
| 2020 | $0.00 | −$661.01 | $14.32 | −$691.18 | — | $577.29 |
| 2021 | $0.00 | −$221.77 | $0.27 | −$264.69 | — | $1,037 |
| 2022 | $0.00 | −$380.51 | $0.88 | −$363.22 | — | $683.66 |
| 2023 | $0.00 | −$376.71 | $1.57 | −$300.10 | — | $347.11 |
| 2024 | $0.00 | −$189.14 | $0.09 | −$173.36 | — | $82.93 |
| 2025 | $0.00 | −$28.42 | $0.00 | −$19.19 | — | $4.69 |
Common questions about Moleculin Biotech
How much does one share of Moleculin Biotech earn?
Over the last 12 months, Moleculin Biotech lost $9.65 for each share.
Does Moleculin Biotech pay a dividend?
Moleculin Biotech didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Moleculin Biotech’s book value per share?
Moleculin Biotech’s book value is $1.63 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Moleculin Biotech have?
Each share of Moleculin Biotech has $1.02 of cash and investments, as of June 30, 2026.
Has Moleculin Biotech bought back shares?
Moleculin Biotech’s share count rose about 10189% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.